1. In-depth immune profiling of peripheral blood mononuclear cells in patients with pancreatic ductal adenocarcinoma reveals discriminative immune subpopulations.
- Author
-
Rodriguez E, Zwart ES, Affandi AA, Verhoeff J, de Kok M, Boyd LNC, Meijer LL, Le Large TYS, Olesek K, Giovannetti E, García-Vallejo JJ, Mebius RE, van Kooyk Y, and Kazemier G
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Receptors, CXCR3 metabolism, Th17 Cells immunology, Th17 Cells metabolism, Receptors, CCR6 metabolism, T-Lymphocytes, Regulatory immunology, Memory T Cells immunology, Th1 Cells immunology, Carcinoma, Pancreatic Ductal immunology, Carcinoma, Pancreatic Ductal pathology, Pancreatic Neoplasms immunology, Pancreatic Neoplasms pathology, Leukocytes, Mononuclear immunology, Leukocytes, Mononuclear metabolism
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year survival of less than 10%. More knowledge of the immune response developed in patients with PDAC is pivotal to develop better combination immune therapies to improve clinical outcome. In this study, we used mass cytometry time-of-flight to undertake an in-depth characterization of PBMCs from patients with PDAC and examine the differences with healthy controls and patients with benign diseases of the biliary system or pancreas. Peripheral blood mononuclear cells from patients with PDAC or benign disease are characterized by the increase of pro-inflammatory cells, as CD86
+ classical monocytes and memory T cells expressing CCR6+ and CXCR3+ , associated with T helper 1 (Th1) and Th17 immune responses, respectively. However, PBMCs from patients with PDAC present also an increase of CD39+ regulatory T cells and CCR4+ CCR6- CXCR3- memory T cells, suggesting Th2 and regulatory responses. Concluding, our results show PDAC develops a multifaceted immunity, where a proinflammatory component is accompanied by regulatory responses, which could inhibit potential antitumor mechanisms., (© 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)- Published
- 2024
- Full Text
- View/download PDF